

NCT00108745 GOG-0212 PRO NCTN/NCORP DATA ARCHIVE

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

J Clin Oncol. 2022 Dec 10;40(35):4119-4128

doi: 10.1200/JCO.22.00146

Epub 2022 Jun 27

PMID: 35759733; PMCID: PMC9746779

Data as of: October 12, 2021

NCT00108745-D2: This dataset contains quality of life (QOL) data from trial NCT00108745 presented in 35759733. NCT00108745-D1 contains patient characteristics and outcome data. NCT00108745-D3 contains adverse event data by organ system. NCT00108745-D4 contains adverse event data by preferred term.

These Data can be used to approximate the published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g. when data must be modified for de-identification purposes or have undergone further data cleaning).

Unless otherwise specified, blank values indicate missing data.

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
1	UPI	char	Universal Patient ID

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
2	age	num	Age (years)

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
3	ntx_s	num	FACT/GOG-Ntx Subscale Score (4 items) at 6 months or prior to cycle 7. Range 0-16. A larger score indicates less neurotoxic symptoms.

<i>Seq</i>	<i>Name</i>	<i>Type</i>	<i>Definition</i>
4	ntx_s_b	num	FACT/GOG-Ntx Subscale Score (4 items) at baseline. Range 0-16. A larger score indicates less neurotoxic symptoms.